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Abstract
Background: International guidelines for variant interpretation in Mendelian disease set stringent criteria to report
a variant as (likely) pathogenic, prioritising control of false-positive rate over test sensitivity and diagnostic yield.
Genetic testing is also more likely informative in individuals with well-characterised variants from extensively
studied European-ancestry populations. Inherited cardiomyopathies are relatively common Mendelian diseases that
allow empirical calibration and assessment of this framework.
Methods: We compared rare variants in large hypertrophic cardiomyopathy (HCM) cohorts (up to 6179 cases) to
reference populations to identify variant classes with high prior likelihoods of pathogenicity, as defined by
etiological fraction (EF). We analysed the distribution of variants using a bespoke unsupervised clustering algorithm
to identify gene regions in which variants are significantly clustered in cases.
Results: Analysis of variant distribution identified regions in which variants are significantly enriched in cases and
variant location was a better discriminator of pathogenicity than generic computational functional prediction
algorithms. Non-truncating variant classes with an EF ≥ 0.95 were identified in five established HCM genes.
Applying this approach leads to an estimated 14–20% increase in cases with actionable HCM variants, i.e. variants
classified as pathogenic/likely pathogenic that might be used for predictive testing in probands’ relatives.
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Conclusions: When found in a patient confirmed to have disease, novel variants in some genes and regions are
empirically shown to have a sufficiently high probability of pathogenicity to support a “likely pathogenic”
classification, even without additional segregation or functional data. This could increase the yield of high
confidence actionable variants, consistent with the framework and recommendations of current guidelines. The
techniques outlined offer a consistent and unbiased approach to variant interpretation for Mendelian disease
genetic testing. We propose adaptations to ACMG/AMP guidelines to incorporate such evidence in a quantitative
and transparent manner.
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Background
Advances in sequencing technology have dramatically
expanded the scope for genetic testing in rare Mendelian
diseases, but have exposed variant interpretation as a
key limiting factor for clinical application. In an effort to
standardise variant assessment in clinical settings, guide-
lines from the American College of Medical Genetics
and Genomics/Association for Molecular Pathology
(ACMG/AMP) were produced in 2015 [1] and have now
been widely adopted [2]. These were in part prompted
by the plethora of erroneous variant-disease associations
in the research literature [3, 4] and the increasing real-
isation that individually rare variants are collectively
common for many genes, as highlighted by population
datasets such as the Exome Aggregation Consortium
(ExAC) [5]. A critical objective of the guidelines is to
limit false-positive results in clinical genetic testing in
order to avoid genetic misdiagnosis or false reassurance
through predictive testing of a variant that is not causal.
The ACMG/AMP guidelines outline how different
lines of evidence should be assessed when interpreting a
variant, and the strength of evidence required for a
pathogenic (or likely pathogenic) classification. However,
they are deliberately broad in scope, with the intention
that individual rules would be interpreted and adapted
for specific diseases within the overall framework [6].
They are conservative in nature and require substantial
evidence in order to classify a variant as disease-causing.
In practice, while novel truncating variants can be classi-
fied as pathogenic (when found in a gene where loss of
function is a known mechanism of disease and fulfilling
other conditions such as rarity), variant-specific evidence
(such as segregation in the family or prior functional evi-
dence of pathogenicity) is required for non-truncating
variants to be reported as pathogenic.
We have recently shown that clinical laboratories uti-
lising these stringent approaches to variant classification
are, as expected, under-calling pathogenic variants in
well-established cardiomyopathy genes [3], prioritising
high specificity at a cost of test sensitivity. Clinical out-
come data from the SHaRe registry of hypertrophic
cardiomyopathy (HCM) patients supports this finding,
as patients with variants of uncertain significance (VUS)
had outcomes intermediate between genotype-positive
and genotype-negative patients, indicating a substantial
proportion are likely to be pathogenic [7]. Some dis-
eases, including cardiomyopathies, are highly genetically
heterogeneous with thousands of distinct causative vari-
ants, many of which are private or only detected in a
handful of families, so interpretation of previously un-
seen variants is essential to provide a molecular diagno-
sis to many patients. As a consequence, the likelihood of
obtaining a positive genetic test result for patients is
often dependent on whether the putative causative vari-
ant has been previously identified and characterised.
Furthermore, the degree of certainty required to con-
sider a specific variant causal in an individual depends
on the use of that information. While predictive testing
or pre-implantation genetic diagnosis requires a high
degree of confidence, some treatment decisions may be
made at lower confidence. In early onset diabetes, a po-
tentially causative variant suggesting possible MODY
(maturity onset diabetes of the young) might trigger a
trial of sulfonylureas even if formally a VUS [8]. Di-
lated cardiomyopathy due to variation in lamin a/c is
associated with a poor prognosis, with a propensity for
life-threatening arrhythmia. A lower threshold for the
use of primary prevention implantable cardioverter
defibrillators may be adopted if a novel variant in
LMNA is identified, even if formally classified as a
VUS and predictive testing would not be undertaken
on the same variant [9–11].
The likelihood of obtaining a positive result, i.e. identify-
ing a pathogenic or likely pathogenic variant, is also
dependent on the ethnicity of the patient. Data from the
Partners Laboratory of Molecular Medicine (LMM) in
the USA showed that Caucasian patients are more
likely to get a positive result in cardiomyopathy genetic
testing than “underrepresented minorities” (including
African-Americans and Hispanics) and that the propor-
tion of patients with inconclusive results was signifi-
cantly greater in both Asians and “underrepresented
minorities” compared to Caucasians [12]. Similar findings
were observed specifically for HCM—the proportion of
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positive/uncertain results was 34.7%/13.9% for Caucasians
and 24.2%/20.6% for non-Caucasians (p < 0.0001) in the
LMM cohort (n = 2912) [13]. One of the likely reasons for
this discrepancy is that much of the research and clinical
testing in this condition has been done in Caucasian-ma-
jority populations, and therefore, Caucasians are more
likely to have a causative variant that has been previously
characterised. Inequalities in healthcare provision and
access to genetic testing in the USA may also exacerbate
this disparity [14]. While more genetic research in non-
Caucasian populations is clearly required, these findings
underline the need for improved variant analysis tech-
niques that reduce the reliance on prior characterisation
of individual variants and better distinguish poorly charac-
terised variants that have a high likelihood of pathogen-
icity from those that are unlikely to be disease-causing.
For genes with a significant excess of rare variation in
case cohorts over the general population, the etiological
fraction (EF) provides a quantitative estimate of the prob-
ability that a rare variant detected in an individual with dis-
ease is causative, and is dependent on the gene, variant
class and variant location within the gene/protein. Here, we
apply this approach in validated HCM genes to empirically
determine the probability that a novel variant found in a
case is pathogenic before considering other evidence and
further expand the framework to identify sub-genic regions
(“hotspots”) in which variants have an increased likelihood
of being actionable. For HCM, an actionable variant refers
to a variant classified as pathogenic or likely pathogenic
that can be used for cascade screening in the family of the
patient being tested, to identify individuals at risk, and
those free from risk, of developing HCM, as recommended
by current guidelines [15]. This provides a more quantita-
tive approach to variant classification, with the aim of ad-
dressing the substantial false-negative rate associated with
current stringent guidelines by increasing the yield of high
confidence pathogenic variants detected in these genes, as
well as enabling a more unbiased application of genetic
testing. We outline a potential framework to integrate this
approach with the ACMG/AMP guidelines for genes and
diseases with available case series to derive these estimates,
enabling such case-control data to be utilised in a more
quantitative and transparent manner. While highlighting
that variant interpretation is highly dependent on the con-
text of gene and disease, this approach is widely applicable
for other Mendelian diseases for which sufficient cases have
been genetically characterised.
Methods
Calculation of etiological fraction for significantly
enriched variant classes
The etiological fraction (EF) estimates the proportion of
risk that can be attributed to a specific exposure, in a
population with disease who have been exposed to a risk
factor [3]. In the context of Mendelian disease, exposure
refers to a rare protein-altering variant in a particular
gene, and the EF estimates the proportion of cases with
a rare variant in whom that variant is disease-causing.
The EF is derived from the attributable risk percent
(ARP) among exposed, i.e. expressing the risk as a pro-
portion rather than a percentage, and derived from the
odds ratio (OR) as described below, where the OR pro-
vides an accurate estimate of the relative risk (RR)—the
ratio of risk among exposed to risk among unexposed
[16]. The odds ratio (OR) is calculated by Altman [17]:
OR ¼ a=bð Þ= c=dð Þ
where a = disease cases with a variant, b = controls/ref-
erence population with a variant, c = disease cases with-
out a variant, and d = controls/reference population
without a variant. The 95% confidence intervals (CI) for
OR values are calculated by:
95%CI ¼ exp ln ORð Þ−1:96  SE ln ORð Þf gð Þ to expð ln ORð Þ
þ 1:96  SE ln ORð Þf gÞ
where the standard error of the log OR was given by:
SE ln ORð Þf g ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
a
þ 1
b
þ 1
c
þ 1
d
r
The EF is derived from the OR:
EF ¼ OR−1ð Þ=OR
95% CIs for EF values are calculated as described by
Hildebrandt et al. [18].
EF and OR values were calculated for both truncating
(frameshift, nonsense, splice donor site, splice acceptor
site) and non-truncating (missense, small in-frame inser-
tions/deletions) variants in HCM genes where a significant
excess of rare variants in cases over the ExAC reference
population was observed [19]. For the eight core sarco-
meric genes (MYBPC3, MYH7, TNNT2, TNNI3, TPM1,
MYL2, MYL3, ACTC1), the case cohorts were derived
from published data from the Oxford Molecular Genetics
Laboratory (OMGL) and the Laboratory of Molecular
Medicine (LMM), Partners Healthcare, comprising be-
tween 4185 and 6179 unrelated HCM probands [3, 13].
The OMGL cohort comprises apparently unrelated index
cases referred from Clinical Genetics centres across the
UK, with initial clinical diagnosis of HCM made by a
consultant cardiologist. Data on patient ethnicity is not
available for this cohort but is expected to be broadly rep-
resentative of the UK population. The LMM HCM cohort
comprised unrelated probands referred for HCM clinical
genetic testing. Any individuals with an unclear clinical
diagnosis of HCM, or with left ventricular hypertrophy
due to an identified syndrome such as Fabry or Danon
disease, or unaffected individuals with a family history
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of HCM were excluded. The LMM cohort was 62%
Caucasian (see Alfares et al. for full details on ethnicity
[13]), but data on ethnicity for individual patients was
not available. For the minor HCM genes (CSRP3, FHL1,
PLN, TNNC1), combined cohorts from OMGL and LMM,
a prospective research cohort from our laboratory and
published cohorts were used as previously described [19],
comprising between 2061 and 5440 unrelated HCM pro-
bands. For FLNC and FHOD3, recently published cohorts
of 448 [20] and 3189 [21] HCM patients respectively were
used. All rare variants were included for these calculations,
regardless of the clinical classification of the variants.
For all genes, ExAC was used as the reference population
database for background variation as previously described
[3]. To account for variable coverage of the exome sequen-
cing in ExAC, the sample total for each gene was adjusted
by calculating the mean number of called genotypes for each
variant. Rare variants were defined as those with a filtering
allele frequency in ExAC below the maximum credible allele
frequency for HCM [22], defined as 4 × 10−5 (prevalence = 1
in 500, allelic heterogeneity = 0.02, penetrance = 0.5, mono-
allelic inheritance, as calculated at http://cardiodb.org/allele-
frequencyapp/). To confirm that this frequency was the
most appropriate threshold to use, a sensitivity analysis was
performed with other thresholds (0.0001, 0.0005, 0.001),
showing that OR and EF values decreased with higher f-
requency thresholds (Additional file 1: Table S1).
EFs as a means of quantifying performance of variant
classifiers
The EF is dependent on the relative frequencies of vari-
ants in cases and population controls. While applying
strict thresholds for rarity will focus on variants more
likely to be disease-causing, thereby increasing the EF, this
is usually not sufficient to adequately distinguish between
benign and pathogenic variation for non-truncating vari-
ants. Therefore, additional methods are required to dis-
criminate between causative and background variants. A
perfect discriminator of pathogenic and benign variants
will identify the proportion of causative variants that is
equal to the case excess and yield an EF of 1.0, with the
proportion of benign variants equal to the population r-
eference frequency of ExAC (and an EF of 0)—see hypo-
thetical example in Fig. 1. In practice, it is unlikely that
full discrimination will be achieved but this EF-based ap-
proach allows us to evaluate methods that aim to differen-
tiate between pathogenic and benign variants. In this
study, we compare the widely used and generic missense
functional prediction scores with gene and disease-specific
variant clustering. This EF-based approach also offers the
advantage of not requiring predefined lists of irrefutable
pathogenic and benign variants, which can be limited
when performing analyses on specific genes.
Assessing performance of missense functional prediction
scores in HCM genes
Functional prediction scores from the dbNSFP database
[23] (version 3.2) were downloaded for all missense
variants in the 13 HCM genes. Eight scores that provide
binary predictions, i.e. damaging vs benign/neutral,
were assessed—fathmm-MKL coding, FATHMM, LRT,
Mutation assessor, MutationTaster, Polyphen2-HDIV,
PROVEAN and SIFT, as well as the CADD algorithm
(damaging variants were defined with a CADD phred
Fig. 1 The use of etiological fractions to evaluate variant classification methods. Illustration of how EFs can be used to evaluate methods for
distinguishing pathogenic from benign variants (for a hypothetical gene). The overall EF of 0.85 [1] is based on a case frequency of 9.5% and a
reference frequency of 1.5%. The aim of variant classification methods is to fully distinguish between pathogenic variants (producing an EF of 1.0
with frequency equal to case excess [2]) and benign variants (producing an EF of 0 with frequency equal to population reference, here ExAC [3]).
We propose that an EF of 0.95 would be required to indicate a likely pathogenic variant
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score ≥ 15). A consensus prediction between the 9 scores
was defined as being damaging if greater than 50% of the
scores that predicted a damaging effect. Additionally, two
consensus algorithms, MetaLR and MetaSVM [24], were
also evaluated. The proportion of available predictions for
each score for all potential missense variants in each gene
was calculated to identify algorithms that do not provide
comprehensive predictions for specific genes.
To test the effectiveness of these prediction scores for
individual HCM genes, missense variants of known con-
sequence (pathogenic and benign missense) were identi-
fied. Pathogenic variants were defined by rarity in ExAC
as described above and:
1) Classified as pathogenic (P) or likely pathogenic
(LP) in HCM patients by two or more clinical
laboratories (OMGL, LMM and ClinVar submitters)
2) Classified as P/LP by one clinical laboratory with no
conflicting classifications (VUS or benign) by other
laboratories
3) Significantly enriched in the OMGL/LMM cohorts
compared to ExAC (Fisher’s exact test)
Benign variants were defined as:
1) Presence in more than one individual in ExAC and
not associated with any disease in ClinVar (P/LP/VUS)
or HGMD
2) Associated with disease in ClinVar (though not P
or LP) or HGMD but at a frequency > 0.001 in ExAC.
The sensitivity (true positive rate) and specificity (true
negative rate) was calculated for the 9 functional predic-
tion scores and 3 consensus scores for each of the 8 core
sarcomeric genes (there were insufficient known patho-
genic variants for the minor genes). As an alternative
method for assessing these predictors, EFs were calcu-
lated for deleterious variants using the case and ExAC
cohorts described above.
Clustering algorithm to detect regional enrichment of
variants
Protein regions enriched for rare variants were identified
using a bespoke unsupervised clustering algorithm de-
veloped within this project. The algorithm is based on a
sliding window scanning the protein sequences from
their N-terminal to C-terminal residues, with a binomial
test used to detect whether there is significant variation
enrichment within the tested window compared with the
rest of the protein.
The results of this first step are influenced by the size of
the sliding window, with a spectrum ranging from small
windows enabling detection of smaller, highly enriched
variation hotspots but prone towards overfitting (in the
most extreme case each residue with multiple variant al-
leles is considered a cluster), to large windows enabling
detection of more extended enriched regions such as large
protein domains but at the risk of too low a resolution (in
the most extreme case, a unique cluster starting at the first
variant residue and ending at the last). In terms of model
performance, the former situation is characterised by spe-
cificity = 1 (no variant-free residues are within clusters)
and sensitivity close to 0 (the vast majority of variant resi-
dues are excluded from clusters), whereas the latter results
in the opposite situation (many variant-free residues are
included in the unique cluster [specificity close to 0] but
also all variant amino-acids are [sensitivity = 1]). For this
reason, the algorithm automatically selects the optimal
window size for each protein by searching for one mini-
mising the difference between sensitivity and specificity
(in this case the mean difference between cases and con-
trols for each gene). Of note, the sparseness of the data
(resulting in a strong imbalance between positive data
points [variant residues] and negative data points [var-
iant-free residues]) make all classic model performance
measures (e.g. accuracy, AUC, PPV) biased towards re-
sults obtained with smaller window sizes.
To look for the optimal window size, the algorithm
starts by testing 19 different sizes ranging from 5% of
the protein to 95%. Subsequently, the algorithm picks
the best one (if any) and tests 18 sizes around it at a
10-fold finer resolution (e.g. if the initial best window
size is 10%, the next iteration will be on windows be-
tween 5.5% and 14.5%). This iterative process is repeated
until a performance plateau is reached (i.e. none of the
18 new window sizes decreases the difference between
sensitivity and specificity by more than 0.001 compared
with the previous iteration). Once the optimal window
size is detected, multiple testing correction is applied to
each definitive window significantly enriched for vari-
ation, on the basis of the average number of times each
protein residue has been tested (which depends on the
number of iterations made, and on the size of the tested
windows). Whenever a significant enrichment is detected
within a window, its coordinates (start/end) are stored
until the whole protein is scanned and, subsequently,
merged with any other significantly enriched window to
obtain a first “raw” set of variation-rich clusters.
After this first step, the algorithm performs a “bound-
ary trimming” procedure at both ends of each cluster.
This step controls for potential inclusion of variant-free
(or non-enriched) distal cluster tails that may have been
included within a significantly enriched window due to var-
iants occurring more proximally. The algorithm performs
the same procedure at both the N- and the C-terminal clus-
ter boundaries, starting with a single-residue window in-
cluding only the most external amino-acid, and iteratively
extending it as far as the cluster median residue. Before
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each extension, the binomial test is used to check if
there is a significant depletion of variants compared
to the rest of the cluster. The algorithm stores each
test’s p value and tested region coordinates and even-
tually trims the cluster by removing the most (if any)
significantly variation-depleted tail, to obtain a final,
refined set of clusters. One last binomial test is per-
formed on the refined clusters to measure the signifi-
cance of their rare variant enrichment.
Distinguishing pathogenic from benign variants using
clustering in case and control cohorts
EFs were calculated based on these clusters and com-
pared to those produced by a consensus of missense
functional prediction scores from the dbNSFP database
[23] (MetaLR, MetaSVM and a consensus of 9 individual
predictors as described above). These consensus scores
were also evaluated in genes where no clustering of case
variants was observed.
Using EFs to increase the yield of putatively pathogenic
variants in HCM cohorts
Sarcomeric gene rare variants in the OMGL/LMM clin-
ical cohort [3] were re-assessed based on the analysis de-
scribed above. The proportion of patients with variants
that would be upgraded to likely pathogenic based on
the revised ACMG/AMP guidelines was calculated, i.e.
those previously classified as VUS but in a variant class
with an EF ≥ 0.95 for missense variants or EF ≥ 0.90 for
inframe indels (as inframe indels will also activate the
PM4 rule regarding variants that change protein length
and therefore only the moderate PM1 rule would be
required for a likely pathogenic classification).
Analysis of prospective HCM cohort
The effect of the new EF-based ACMG/AMP rules on the
yield of actionable variants was assessed on a prospective
cohort of 684 HCM patients recruited at the Royal
Brompton & Harefield Hospitals NHS Foundation Trust,
London, UK [19]. The ACMG/AMP rules described below
were used to classify variants from the valid HCM genes
defined in this study, with rule implementation as de-
scribed in the CardioClassifier resource [6]. The following
rules could be activated by automated script:
 PM2—filtering allele frequency in ExAC < 4 × 10−5.
This rule must be activated to denote a causative
variant for this analysis.
 PVS1—truncating variants in MYBPC3, TNNT2,
TNNI3, CSRP3, FHL1, PLN (genes statistically
enriched in HCM cohorts versus ExAC).
 PS4—individual variant statistically enriched in cases
over controls, based on LMM/OMGL cohort versus
ExAC with the rule activated if the case count was > 2
and the Fisher’s exact test p value < 1.79 × 10−6
(Bonferroni correction).
 PM4—protein length changing variant, i.e. an
inframe indel or stop lost variant.
 PP3—missense variant with multiple lines of
computational evidence suggesting a deleterious
effect, i.e. of the 8 predictors assessed (SIFT,
PolyPhen2 var., LRT, Mutation Taster, Mutation
Assessor, FATHMM, CADD and Grantham scores),
only 1 predicts benign and < 3 have unknown
classifications, or if ≥ 3 have unknown classifications,
all others predict damaging.
 PM5/PS1—novel missense change at an amino acid
where a different missense variant is pathogenic
(PM5) or novel missense variant with same amino
acid change as an established pathogenic variant
(PS1). Pathogenicity here is defined as a pathogenic
classification in ClinVar by multiple submitters with
no conflicting evidence.
Rare variants (i.e. with rule PM2 activated) were then
manually assessed for human genetic evidence in ClinVar
entries and published reports using the following rules:
 PP1—co-segregation with disease. This rule was
defined as supporting for ≥ 3 observed meioses,
moderate for ≥ 5 meioses and strong for ≥ 7 meioses.
 PS2/PM6—de novo inheritance (with/without
confirmed paternity and maternity).
 The PS3 rule relating to effects in functional studies
was not applied due to the lack of standardisation
and validation in functional assays for HCM
variants.
The number of patients with variants that still remained
as VUS, i.e. unactionable according to current guidelines,
but that would be upgraded to at least likely pathogenic
based on the revised ACMG/AMP guidelines was calcu-
lated as described for the clinical HCM cohort, i.e. those
in a variant class with an EF ≥ 0.95 for missense variants
(activating PM1_strong) or EF ≥ 0.90 for inframe indels
(activating PM1_moderate).
Genotype-phenotype analyses to validate variant
pathogenicity
The clinical characteristics of two HCM cohorts were used
to support the pathogenicity of variants upgraded on the
basis of an EF ≥ 0.95. For the prospective HCM cohort, left
ventricular (LV) mass values indexed to body surface area
were derived from cardiac magnetic resonance imaging
and compared between cases with pathogenic or likely
pathogenic variants (current ACMG/AMP guidelines),
VUS upgraded to likely pathogenic with EF rules, other
VUS and genotype-negative cases (only variants in thick
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filament genes MYH7 and MYBPC3 were analysed due to
the distinctive patterns of LV hypertrophy observed in
cases with variants in thin filament genes [25]).
Outcome data was assessed using the Sarcomeric Hu-
man Cardiomyopathy Registry (SHaRe), a multi-centre
international repository that aggregates clinical and genetic
data from patients with cardiomyopathies including HCM.
A total of 2694 HCM patients with both right-censored
outcome data and known sarcomeric genotype were ana-
lysed—1254 patients with at least one pathogenic or likely
pathogenic variant in any of the 8 sarcomeric genes; 1199
patients with no sarcomeric variants; and 241 patients with
VUS in any of the sarcomeric genes. Of the 241 patients
with VUS, 69 were reclassified as pathogenic as they had
variants with an EF ≥ 0.95. Survival curves were calculated
by Kaplan-Meier analysis with log-rank test for the propor-
tion of patients free of the overall composite outcome for
each of the four genotype groups [7].
Detection of enriched variant clusters in RYR2
Non-truncating variants in RYR2 are causative in up to
50% of patients with catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), a rare inherited arrhythmia
affecting approximately 1 in 10,000 people. Variants in
cases have been shown to cluster in specific regions of
RYR2, which codes for a ryanodine receptor 4867 amino
acids in length, with a subset of its 105 exons thought to
account for the majority of disease-causing variation [26].
However, the relatively high level of background benign
variation in RYR2 increases the uncertainty in interpreting
novel variants detected in CPVT cases [27]. For RYR2
variants in CPVT, rare variants were defined as those with
a filtering allele frequency in ExAC below the max-
imum credible allele frequency for CPVT [22], defined
as 1 × 10−5 (prevalence = 1 in 10,000, allelic heterogen-
eity = 0.1, penetrance = 0.5, monoallelic inheritance, as
calculated at http://cardiodb.org/allelefrequencyapp/).
For variants without a filtering allele frequency, i.e. de-
tected in a maximum of one individual for any major
ExAC sub-population, those with an overall ExAC allele
count less than three were deemed to be rare. All mis-
sense and single amino acid inframe insertions/dele-
tions were included as non-truncating variants.
Case clusters were defined as described above using a re-
cently published cohort of 1200 referral cases for CPVT
and 155 well-phenotyped cases (78 classified as strong
CPVT and 77 classified as possible CPVT) [27]. For cal-
culating EFs, only the 1200 referral cases were used for
comparison with ExAC. Although this will yield more
conservative EFs than using definitively diagnosed cases
or a mix of diagnosed and referral (the yield of RYR2
variants in the referral series was 18.2% compared to
59% in the well-phenotypes cases [27]), the EFs gener-
ated will be more relevant and applicable to real world
referral genetic testing for CPVT. We compared results
from our detected clusters with previously defined hot-
spot regions (exons 3–15, 44–50, 83–90 and 93–105)
[26] and a recently refined set of exons based on variant
enrichment in cases (3, 8, 14, 43, 47–49, 81, 83, 88–90,
93, 95, 97–101, 103, 105), using the same case cohort
as here but calculated on an exon-by-exon basis [27].
Results
In established HCM-associated genes, the majority of rare
variants found in cases are pathogenic
We compared the prevalence of rare variants of different
classes in established HCM-associated genes between
HCM cases and population controls, and calculated the
odds ratio (OR) for disease. From this, we derived the
etiological fraction (EF) which, under a Mendelian disease
model, provides an estimate of the proportion of rare vari-
ants found in affected individuals that are disease-causing,
and therefore, the probability that an individual variant
(found in a patient with disease) is pathogenic.
The etiological fraction (EF) and odds ratio (OR) for
predicted non-truncating (missense, small in-frame in-
sertions/deletions) and predicted truncating (frameshift,
nonsense, splice donor site, splice acceptor site) variants
in validated HCM genes [19] are shown in Table 1.
Truncating variants in MYBPC3, which we can estimate
based on case and reference frequencies are causative in
over 9% of HCM cases, have an EF>0.99 confirming that
this variant class has a high likelihood of pathogenicity
concordant with pedigree and functional studies. Trun-
cating variants in other genes with an excess over ExAC are
less prevalent (occurring in < 0.2% of cases in each gene),
but the probability that a variant found in a case is causal is
nonetheless high (> 0.84). While non-truncating variants
are more prevalent in the general population, leading to a
lower signal to noise ratio and reduced interpretative confi-
dence for individual variants, the majority of such variants
are causal, when found in an individual with confirmed dis-
ease. However, at the gene level, only variants in TPM1
yield an EF ≥ 0.95.
Evaluation of missense functional prediction scores
The EF can be used to assess variant prioritisation algo-
rithms, empirically estimating the proportion of variants
that are pathogenic after applying a filter or prioritisa-
tion strategy. Some of the most commonly used tools for
evaluating variants are missense functional prediction
algorithms.
To initially evaluate the performance of these compu-
tational algorithms for HCM gene variants, the results
of nine predictors (FATHMM, fMKL, LRT, mutation
assessor, mutation taster, Polyphen-2, PROVEAN and
SIFT, as well as CADD which integrates multiple anno-
tations into one metric) and three consensus methods
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(MetaLR, MetaSVM [24] and a consensus of the nine al-
gorithms) from the dbNSFP database [23] were assessed
using known pathogenic (n = 298) and benign (n = 349)
variants in the eight sarcomeric genes (see the “Methods”
section). These algorithms generally provide high sen-
sitivity but limited specificity, as has been previously
reported, although in contrast the FATHMM predictor
(and MetaLR and MetaSVM consensus scores that
incorporate FATHMM) has a low sensitivity for detec-
tion of pathogenic variants for MYBPC3 and MYL2
(Additional file 1: Table S2). We also noted that
dbNSFP does not provide predictions for certain gene/
algorithm combinations (Additional file 1: Table S3).
Clustering analysis identifies interpretable “hot spots”,
within which novel variants have a high probability of
pathogenicity
For genes with an EF < 0.95 for rare non-truncating
variants, we examined the regional distribution of variants
found in cases along the protein sequence. A novel clus-
tering algorithm (see the “Methods” section) identified a
statistically significant aggregation of distinct variants (in
cases) in 6 genes—MYH7, MYBPC3, TNNI3, TNNT2,
MYL3 and CSRP3 (Fig. 2, Additional file 1: Table S4). For
each cluster, the prevalence of rare variants in cases and
controls was then used to calculate the EF as described
above. Variants in four of these clusters (MYH7,
MYBPC3, TNNI3, TNNT2) had an EF > 0.95 (Table 2).
The regions highlighted by clustering analysis corres-
pond to key functional and protein-binding domains—
the myosin motor domain of MYH7, troponin C and
actin-binding domains in TNNI3 and the tropomyosin-
binding domain in TNNT2.
FLNC [28] and FHOD3 [21] have recently been proposed
as novel genes for HCM, with both reports demonstrating
an excess of rare variation over controls as well as strong
supporting familial segregation data. However, the relative
frequencies of rare variation between cases and ExAC in
these two genes produce only modest overall EFs (0.44 for
FLNC and 0.48 for FHOD3). Although enrichment of case
variants towards the C-terminus of FLNC has previously
been noted [20, 28], no clusters were detected in this
Table 1 Etiological fractions and odds ratios for established HCM genes
Gene Transcript Number of cases Case frequency
(variants/total)
ExAC frequency
(variants/total)
p value Odds ratio (OR) Etiological fraction (EF)
Non-truncating variants
MYH7 ENST00000355349 6112 13.89% (849/6112) 1.11% (672/60,469) < 0.0001 14.4 (12.9–15.9) 0.930 (0.923–0.938)
MYBPC3 ENST00000545968 6179 9.35% (578/6179) 1.21% (555/45,794) < 0.0001 8.4 (7.5–9.5) 0.881 (0.868–0.895)
TNNT2 ENST00000367318 6103 1.69% (103/6103) 0.15% (86/57,018) < 0.0001 11.4 (8.5–15.2) 0.912 (0.889–0.935)
TNNI3 ENST00000344887 6047 2.10% (127/6047) 0.15% (79/52,607) < 0.0001 14.3 (10.8–18.9) 0.930 (0.912–0.948)
TPM1 ENST00000403994 4447 1.44% (64/4447) 0.07% (42/58,642) < 0.0001 20.4 (13.8–30.1) 0.951 (0.933–0.969)
MYL2 ENST00000228841 4185 1.03% (43/4185) 0.11% (69/60,521) < 0.0001 9.1 (6.2–13.3) 0.890 (0.851–0.930)
MYL3 ENST00000395869 4185 0.84% (35/4185) 0.14% (85/60,605) < 0.0001 6.0 (4.0–8.9) 0.833 (0.772–0.895)
ACTC1 ENST00000290378 4185 0.53% (22/4185) 0.06% (37/60,198) < 0.0001 8.6 (5.1–14.6) 0.884 (0.826–0.941)
PLN ENST00000357525 5440 0.17% (9/5440) 0.02% (15/60,475) < 0.0001 6.7 (2.9–15.3) 0.850 (0.737–0.964)
CSRP3 ENST00000533783 4866 0.62% (30/4866) 0.19% (115/60,647) < 0.0001 3.3 (2.2–4.9) 0.694 (0.579–0.808)
FHL1 ENST00000370690 2061 0.78% (16/2061) 0.09% (53/60,278) < 0.0001 8.9 (5.1–15.6) 0.888 (0.826–0.949)
TNNC1 ENST00000232975 3335 0.24% (8/3335) 0.06% (33/59,192) 0.0013 4.3 (2.0–9.3) 0.768 (0.598–0.938)
FLNC ENST00000325888 448 3.79% (17/448) 2.15% (1225/56,897) 0.0314 1.8 (1.1–2.9) 0.442 (0.172–0.712)
FHOD3 ENST00000590592 3189 2.26% (72/3189) 1.20% (683/57,035) < 0.0001 1.9 (1.5–2.4) 0.475 (0.353–0.597)
Truncating variants
MYBPC3 ENST00000545968 6179 9.16% (566/6179) 0.09% (40/45,794) < 0.0001 115.3 (83.6–159.1) 0.991 (0.988–0.995)
TNNT2 ENST00000367318 6103 0.18% (11/6103) 0.03% (17/57,018) < 0.0001 6.1 (2.8–12.9) 0.835 (0.722–0.948)
TNNI3 ENST00000344887 6047 0.08% (5/6047) 0.01% (5/52,607) 0.0019 8.7 (2.5–30.1) 0.885 (0.757–1.013)
PLN ENST00000357525 5440 0.17% (9/5440) 0.01% (4/60,475) < 0.0001 25.1 (7.7–81.4) 0.960 (0.917–1.003)
CSRP3 ENST00000533783 4866 0.14% (7/4866) 0.02% (14/60,647) 0.0006 6.2 (2.5–15.5) 0.840 (0.705–0.974)
FHL1 ENST00000370690 2061 0.15% (3/2061) 0.00% (0/60,278) < 0.0001 205.0 (10.6–3969.8) 0.995 (0.981–1.009)
Displayed are the cumulative frequency of rare variants (rare defined by ExAC filtering allele frequency < 4 × 10−5 [22]), Fisher’s exact test p values and estimates
of odds ratio and etiological fraction (with 95% confidence intervals) for non-truncating and truncating variants in HCM genes. The etiological fraction can be
interpreted as an estimate of the probability that a rare variant, found in an individual with HCM, is causative. This suggests that the majority of variants are
pathogenic when detected in cases, and for some genes, the probability that an individual variant is pathogenic is > 0.9, before considering variant-specific
segregation of functional data. Only variant classes with a significant excess of variants in case cohorts over ExAC are displayed
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study, though this may be due to the limited cohort size
available (448 cases [20]). For FHOD3, a cluster between
residues 321 and 849 was detected but still yielded a
relatively modest EF of 0.78 (0.73–0.85) and OR of 4.7
(3.5–6.3) (Additional file 2: Figure S2). The authors of the
FHOD3 study noted a clustering of case variants in the
small coiled-coil domain (residues 622–655) although the
EF for this region only reached 0.82 (OR = 5.6).
The performance of variant clustering and functional pre-
diction scores in distinguishing between pathogenic and
benign variants was then compared. In contrast to the sig-
nificant enrichment of pathogenic variants obtained by ana-
lysis of the regional distribution of variation, functional
prediction consensus scores only marginally increased EFs,
compared to whole-gene estimates (Table 2), highlighting
the limitations of using such generic predictors. For other
HCM genes, no clear clustering of variants in the case
cohorts was observed across the protein sequence
(Additional file 2: Figure S1). Therefore, only consen-
sus functional prediction scores are currently available
for variant prioritisation, but again these provide only
a marginal increase in EF values for these genes
(Additional file 1: Table S5).
Adapting ACMG/AMP guidelines to incorporate EF prior
probabilities
The ACMG/AMP guidelines incorporate the relative fre-
quency of an individual variant in cases and controls as dir-
ect evidence of disease association (PS4). This rule is
applicable only for the minority of individual HCM variants
that are recurrently observed in large case series. For
non-truncating variants, there are currently two further
rules in the ACMG/AMP guidelines that can incorporate
information on the differing aggregate frequencies of
Fig. 2 Distribution of rare variants in HCM and ExAC cohorts for 6 genes with HCM clustering. Clustering analyses identify regions enriched for
disease-associated variation, and therefore within which variants have a high likelihood of pathogenicity. For six HCM genes, the location of rare
missense and single amino acid inframe indel variants found in cases (all variants regardless of clinical classification) and controls are shown
alongside a cartoon of the cDNA structure. Darker grey indicates higher variant density (overlapping variants not plotted separately). Regions in
which variants cluster significantly in cases are shown in red, and regions with clustering in population controls (ExAC) are shown in yellow. The
HCM clusters detected were: MYH7 (residues 167–931), MYBPC3 (485–502, 1248–1266), TNNI3 (141–209), TNNT2 (79–179), MYL3 (143–180) and
CSRP3 (44–71). For MYH7, existing functional annotations (as described in the “Discussion” section) are superimposed: In green, key residues of
the converter kinetic domain and myosin mesa surface area enriched in disease-associated variants (Homburger et al. [37]); in blue, sites of inter-
and intramolecular interaction between pairs of myosin heads (Alamo et al. [38]); and in grey, regions previously identified as constrained
(intolerant of variation as evidenced by depletion of protein-altering variation in population controls), with the darker shades indicating higher
constraint (Samocha et al. [36]). The coordinates describe amino-acid position within the canonical protein sequence
Walsh et al. Genome Medicine            (2019) 11:5 Page 9 of 18
variants of particular classes between case and control co-
horts and that can be activated by novel variants—PP2
(missense in gene with a low rate of benign missense vari-
ants and pathogenic missense variants are common) and
PM1 (mutational hot spot or well-studied functional do-
main without benign variation). However, activating even
the stronger of these rules (PM1) will not lift any novel or
relatively uncharacterised variant beyond VUS without sub-
stantial segregation or functional characterisation, even if
found in genes or regions that are completely intolerant of
variation. Additionally, the rules are categorical (despite de-
scribing a quantitative class of evidence) and must be speci-
fied for each gene and disease, with no consensus yet on
the circumstances in which these should be applied.
In order to apply a more quantitative approach to these
rules, we propose an adaptation of the guidelines as shown
in Fig. 3. The EF enables a unified approach and provides
an empirical estimate of the probability of pathogenicity
for a variant in a given gene (or region of a gene) that
allows rules to be applied at different strengths. The
non-quantitative related rules PP2 and PM1 would be
replaced with a single rule (PM1) with three (or more) evi-
dence levels depending on pre-defined EF for the relevant
variant class. For genes where clustering of variants has
been observed, regional EFs, rather than EFs at the gene
level, should be applied. This semi-quantitative approach
is similar to the PP1 rule for segregation data that allows
the rule to be progressed from supporting to moderate to
strong with increasing evidence [29, 30]. As the EF is cal-
culated for rare variants found in cases, PM1 would only
be activated in combination with the PM2 rule defining
rarity, and if the variant has been identified in an individ-
ual suspected to have cardiomyopathy. Since PM1_strong
(in conjunction with PM2) would enable a novel variant
Table 2 Refinement of etiological fractions for 6 HCM genes using variant clustering and functional prediction scores
Gene Case
excess
EF (whole gene) Predictor
method
Prioritised variants Variants not prioritised
Case freq. EF Case freq. EF
MYH7 12.76% 0.930 (0.923–0.938) HCM cluster 10.70% 0.976 (0.972–0.981) 3.17% 0.746 (0.706–0.785)
Consensus 12.55% 0.940 (0.933–0.947) 1.32% 0.783 (0.728–0.839)
MetaSVM 12.53% 0.944 (0.937–0.951) 1.34% 0.739 (0.675–0.804)
MetaLR 13.29% 0.944 (0.938–0.951) 0.58% (p = 0.0155) 0.406 (0.185–0.627)
MYBPC3 7.98% 0.879 (0.865–0.893) HCM cluster 2.80% 0.979 (0.971–0.987) 6.39% 0.830 (0.809–0.850)
Consensus 8.42% 0.904 (0.892–0.916) 0.77% 0.524 (0.379–0.670)
MetaSVM 4.27% 0.945 (0.934–0.957) 4.92% 0.811 (0.786–0.837)
MetaLR 1.78% 0.900 (0.874–0.925) 7.41% 0.871 (0.855–0.887)
TNNT2 1.54% 0.912 (0.889–0.935) HCM cluster 1.23% 0.958 (0.941–0.974) 0.46% 0.787 (0.699–0.874)
Consensus 1.20% 0.909 (0.880–0.937) 0.49% 0.832 (0.730–0.934)
MetaSVM 1.11% 0.894 (0.861–0.927) 0.58% 0.905 (0.848–0.961)
MetaLR 1.11% 0.889 (0.856–0.923) 0.58% 0.921 (0.872–0.971)
TNNI3 1.95% 0.930 (0.912–0.948) HCM cluster 1.92% 0.974 (0.963–0.984) 0.18% (p = 0.0918) 0.457 (0.140–0.774)
Consensus 1.93% 0.957 (0.943–0.970) 0.17% (p = 0.0383) 0.566 (0.280–0.852)
MetaSVM 1.77% 0.939 (0.921–0.957) 0.33% 0.873 (0.803–0.944)
MetaLR 1.87% 0.932 (0.913–0.951) 0.23% 0.903 (0.833–0.973)
MYL3 0.70% 0.833 (0.772–0.895) HCM cluster 0.55% 0.925 (0.886–0.965) 0.29% (p = 0.0021) 0.655 (0.455–0.856)
Consensus 0.79% 0.869 (0.817–0.921) 0.05% (p = 0.6503) 0.310 (0–1)
MetaSVM 0.50% 0.840 (0.763–0.917) 0.34% 0.833 (0.735–0.930)
MetaLR 0.53% 0.809 (0.722–0.897) 0.31% 0.883 (0.809–0.958)
CSRP3 0.41% 0.683 (0.563–0.803) HCM cluster 0.43% 0.882 (0.821–0.943) 0.16% (p = 0.5533) 0.158 (0–0.724)
Consensus 0.58% 0.735 (0.630–0.839) 0.02% (p = 1.0000) –
MetaSVM 0.53% 0.779 (0.687–0.871) 0.07% (p = 1.0000) –
MetaLR 0.55% 0.751 (0.651–0.852) 0.05% (p = 1.0000) –
Comparison of performance of variant clustering and consensus functional prediction scores in enriching for disease-associated non-truncating/missense variants
in 6 HCM genes where the clustering of case variants was detected. For each gene, the EF of all rare variants is shown, followed by the EF of variants prioritised
by the approach, and the EF of the remaining variants that are not prioritised. Clustering analyses identified regions of 4 genes with an EF ≥ 0.95 (bold), and
generally outperformed consensus functional prediction scores. Fisher’s exact p values for comparison of rare variation in cases and ExAC reference samples were
< 0.0001 unless otherwise noted. For MYBPC3 (italics), the FATHMM predictor was not included in the consensus scores due to its poor performance for this gene,
which also affected the MetaSVM and MetaLR consensus scores
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to be classified as likely pathogenic, we suggest an
EF ≥ 0.95 could activate this rule. This is equivalent
to an OR of 20, broadly similar to that adopted in the
Bayesian modelling of the ACMG/AMP guidelines by
Tavtigian et al. [31].
Since each level of evidence in the hierarchical
ACMG/AMP framework represents a doubling in
weight, a Bayesian interpretation of the ACMG/AMP
guidelines [31] requires that the odds should increase
by a power of 2 as you move to a higher evidence tier.
This yields corresponding EF/OR thresholds of 0.776/
4.47 for the PM1_moderate rule and 0.527/2.11 for the
PM1_supporting rule given an EF threshold of 0.95 for
PM1_strong. However, we believe a more conservative
application of these rules may be more appropriate in a real
world setting, and therefore for this study, we have defined
PM1_moderate as an EF between 0.90 and 0.95 (minimum
OR of 10) and PM1_supporting as an EF between 0.80 and
0.90 (minimum OR of 5). Future consensus-derived imple-
mentations of these rules may choose to incorporate the
Bayesian model, although it should be noted that other
recommendations for translating quantitative data into
ACMG/AMP rules also do not account for exponentially
scaled odds of pathogenicity [29, 30].
An EF-calibrated tiered application of PM1 increases the
yield of actionable variants in HCM
To evaluate how the EF-based modified ACMG/AMP
guidelines could improve the yield of genetic testing in
HCM, we determined the proportion of VUS in a diag-
nostic referral cohort that were found in genes or
regions with an EF ≥ 0.95 that might therefore trigger a
PM1_strong rule (i.e. non-truncating variants through-
out TPM1 and in case-enriched clusters of MYH7,
MYBPC3, TNNI3 and TNNT2). In all, variants in 4.0%
of cases could be upgraded to likely pathogenic by acti-
vating this strong evidence rule (Fig. 4a). This repre-
sents an increase in yield of pathogenic and likely
pathogenic variants in the eight sarcomeric genes from
28.8% to at least 32.8% (14% relative increase) in this co-
hort. It should be noted this is a conservative estimate,
focusing only on PM1_strong, whereas variants activat-
ing PM1_moderate and PM1_supporting might also
lead to a change in interpretation when combined with
other lines of existing evidence.
Sarcomeric variants in a prospective cohort of 684
HCM cases [19] were also analysed. 19.1% of cases had ac-
tionable (pathogenic and likely pathogenic) variants with
automatically applied rules (see the “Methods” section for
details), with only 4 additional cases with VUS upgraded
to actionable based on manual assessment of published
evidence from family pedigrees. In contrast, VUS would
be upgraded in 31 cases (of 82 with VUS) using the pro-
posed PM1 modifications (4.5% of the cohort) in addition
to automatically applied rules. In total, this corresponds to
a 20.7% relative increase in actionable variants over
current guidelines (Fig. 4b). See Additional file 1: Table S6
for details of the variants detected in this cohort.
Fig. 3 Proposed adaptation of ACMG/AMP guidelines for rule PM1, relating to the relative frequencies of non-truncating variants in case cohorts
and population controls
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Independent validation of variants upgraded from VUS
under this framework
The distinctive clinical characteristics of genotype-positive
and genotype-negative HCM patients offer an opportunity
to validate variant classifications in the absence of an
independent gold-standard set of variants for benchmark-
ing. If cases with variants that are upgraded from VUS to
P/LP are more phenotypically similar to cases with known
pathogenic variants, this offers further supportive evi-
dence to validate the reclassification. We assessed mean
Fig. 4 Effect of EF-based approach to variant classification in HCM cohorts. a Proportion of cases from the OMGL/LMM HCM cohorts with variants
in 8 sarcomeric genes (only rare variants, ExAC filtering frequency < 4 × 10−5, are shown, excluding non-essential splice site variants). Coloured
shading represents the clinical classification of the original diagnostic laboratory (OMGL and LMM), and, for variants originally classified as VUS,
the proportion that could be reclassified as Likely Pathogenic based on occurrence within a gene or region with EF ≥ 0.95. Eighty-nine variants in
123 cases for MYH7, 12 variants in 27 cases for MYBPC3, 18 variants in 34 cases for TNNI3, 15 variants in 18 cases for TNNT2 and 22 variants in 33
cases for TPM1 would be upgraded based on this analysis. b Proportion of cases in a prospective HCM cohort classified as actionable based on
application of fixed and automatable ACMG/AMP rules, alongside the addition of manual curation of published evidence and the proposed
EF-calibrated PM1 rules. Thirty-one extra cases (4.5%) are upgraded with EF-based rules compared to just 4 (0.6%) with manual curation. c
Comparison of indexed LV mass in cases with pathogenic variants, VUS in high EF (≥ 0.95) regions, and VUS in low EF regions (< 0.95) in MYH7/
MYBPC3 as well as genotype-negative cases, from the prospective HCM cohort. The clinical phenotype of individuals with VUS at locations
anticipated to be pathogenic is indistinguishable from known pathogenic/likely pathogenic variants, while individuals with VUS in other regions
have a clinical phenotype more similar to individuals without a sarcomere variant. d Kaplan-Meier survival curve for the overall composite
endpoint (including mortality, ventricular arrhythmia and heart failure composites) of the SHaRe cardiomyopathy registry stratified by genotype
(HCM cases with pathogenic variants, VUS in high EF region (≥ 0.95), VUS in lower EF regions (< 0.95), and genotype-negative cases)
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indexed left ventricular (LV) mass and event-free survival
as clinical variables that are associated with pathogenic
sarcomere variants.
In the prospective HCM cohort, overall LV mass is signifi-
cantly greater in genotype-negative cases (101.0 ± 31.8 g/m2)
compared to genotype-positive cases (88.7 ± 31.1 g/m2), des-
pite the fact that patients with pathogenic sarcomeric vari-
ants tend to have greater maximum LV wall thickness.
Cases with variants upgraded from VUS were similar to
genotype-positive (86.0 ± 28.1 g/m2, p = 0.98), with both
significantly different from genotype-negative and cases with
VUS that are not upgraded (104.3 ± 24.7 g/m2) (Fig. 4c).
Genotype-positive cases have significantly worse outcomes
than genotype-negative cases, as demonstrated most com-
prehensively by data from the SHaRe registry [7]. In this
dataset, cases with VUS display intermediate outcomes,
although more similar to genotype-positive (p = 0.07)
than genotype-negative (p < 0.001). Sub-classifying these by
EF, cases with VUS with an EF ≥ 0.95 had similar outcomes
to genotype-positive cases (p = 0.9) and were significantly
different to genotype-negative cases (p = 0.001) (Fig. 4d). In
contrast, cases with VUS with an EF < 0.95 displayed cumu-
lative outcomes intermediate between genotype-positive
(p = 0.03) and genotype-negative (p = 0.03) cases, consistent
with the expectation that these cases will include a mix of
both pathogenic and rare benign variants.
Applicability of this approach to other genetic diseases
To assess how the approach described here could be
applied to other genetic diseases, we analysed variants in
RYR2 from a recently published referral cohort for cate-
cholaminergic polymorphic ventricular tachycardia (CPVT)
[27]. Rare, non-truncating RYR2 variants detected in 1200
referral cases and 155 well-phenotyped CPVT cases were
used to define three case-enriched clusters in RYR2 (resi-
dues 2138–2538, 3935–4196 and 4721–4959), partially
overlapping with previously identified disease hotspots
(Fig. 5). EF and OR values were calculated by comparison
of the 1200 referral cases to ExAC. Despite the use of a
referral only case cohort (which has been shown to have a
significantly lower yield of RYR2 variants), the EF for
rare variants within the clusters was calculated at 0.982
(OR = 55.5) (Additional file 1: Table S7). Although RYR2
has a relatively high background rate of rare variants, by
setting stringent population frequency thresholds (see the
“Methods” section) and identifying enriched clusters, we
can identify variant classes with a very high probability of
pathogenicity—indeed the EF will be higher still for
definitively diagnosed CPVT cases given the relatively low
diagnostic yield observed in the referral cohort. Our un-
supervised approach to defining variant-enriched clusters
was more discriminatory than an exon-based strategy—
the original 41 exon hotspot region [26] yielded an EF
of 0.966 (OR = 29.2) and the recently refined 21 exon
hotspot region [27] yielded an EF of 0.975 (OR = 39.8)
(Additional file 1: Table S7), though the larger clusters
do encompass more case variants. The limitations of using
exon boundaries to define hotspots are highlighted by
exon 90 (the largest RYR2 exon) in which pathogenic
variants appear to be restricted to the first half of the
exon (Fig. 5).
Discussion
The accurate and comprehensive interpretation of rare
variants underlying Mendelian disease remains one of
the principal challenges facing genetics and one of the
key obstacles to fulfilling the potential of genomics in
clinical practice. Current guidelines are conservative and
prioritise minimising false-positive results, given the po-
tentially serious adverse consequences of predictive test-
ing based on erroneously classified variants. However,
this comes at the cost of sensitivity and denies many in-
dividuals the benefits of a molecular diagnosis. In HCM,
case-control comparisons have highlighted that the ma-
jority of sarcomeric gene variants reported as VUS in
leading clinical labs are in fact pathogenic variants, par-
ticularly for population groups that have not been exten-
sively studied, highlighting the need for improved
stratification of these variants. While the principal benefit
of a molecular diagnosis in HCM is currently the
Fig. 5 Distribution of rare variants in CPVT and ExAC cohorts for RYR2. All rare RYR2 non-truncating (missense and single amino acid inframe
indel variants) variants in 1355 CPVT cases (well-phenotyped and referral) and ExAC are shown alongside a cartoon of the cDNA structure. Darker
grey indicates higher variant density (overlapping variants not plotted separately). Three regions enriched for disease-associated variation were
identified (shown in red)—residues 2138–2538, 3935–4196 and 4721–4959. Exons used in previously defined hotspot regions (original 41 exons
and refined 21 exons) are highlighted as shown
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potential for predictive testing of relatives, for applica-
tions of genetic testing other than diagnosis and predict-
ive testing (such as prognostication and selection of
specific therapies, that are emerging in HCM and estab-
lished in other diseases), a different balance between sensi-
tivity and specificity may be required, and variants may be
actionable with a lower burden of proof of causality. It is
also recognised that VUS, though not clinically actionable,
can create uncertainty and confusion for recipients of
genetic testing, with patients often over-interpreting their
effect [32]. New methods for more comprehensive identifi-
cation of disease-causing variants, while maintaining the
stringency of clinical guidelines, are urgently required.
In this study, we have demonstrated that using large
case and population cohorts, and applying strict popula-
tion frequency thresholds for variants of interest, we can
identify genes and gene regions in which variants of
specific classes have high likelihoods of pathogenicity.
The probability of pathogenicity can also be empirically
estimated, providing a quantitative measure of interpret-
ative confidence. We demonstrate how the ACMG/AMP
framework could be adjusted to incorporate this infor-
mation (where suitable case series exist) and enable a
more quantitative and transparent assessment of this evi-
dence class. Crucially, this new framework allows variants
that are novel or otherwise not yet well-characterised, but
which belong to variant classes with very high prior prob-
abilities of pathogenicity, to be classified as (likely) patho-
genic. Under existing rules, such variants will remain as
VUS unless the family structure permits well-powered
segregation analysis, or there are resources for functional
characterisation.
As variant-specific evidence such as co-segregation data
has typically been required to classify missense or
non-truncating variants as disease-causing, we recognise
that the novel approach to variant classification described
here may require further piloting and replication before
adoption of a clinical setting. However, we believe this
method is consistent with the stringent approach to vari-
ant classification of current guidelines. While the ACMG/
AMP guidelines define likely pathogenic as a “greater than
90% certainty of a variant being disease-causing” [1], a
95% threshold is arguably more in line with standard clin-
ical practice, and therefore, we have proposed an EF
cut-off of 0.95 to define strong evidence for this rule. We
consider a 95% probability of pathogenicity to be a reason-
able level of evidence for a “likely pathogenic” classifica-
tion, and one that provides an effective balance between
sensitivity and specificity in genetic testing. It is also im-
portant to recognise that there is an inherent uncertainty
associated with all variant interpretation, particularly for
those classified as likely pathogenic. The confidence of
both clinicians and patients in the results of genetic test-
ing could be improved by more effective reporting of the
evidence for pathogenicity in genetic reports, including
the EF for relatively uncharacterised variants, and more
transparency about the level of certainty associated with
any classification.
Importantly, the approach to variant classification de-
scribed here is compatible with the existing framework of
the ACMG/AMP guidelines that have been widely adopted
in clinical genetics laboratories. The translation of EF
values into semi-quantitative PM1 rules, with a twofold
increase in ORs required to progress between evidence
classes, is similar to that adopted for another quantitative
data type—co-segregation with disease in affected family
members. Recent studies have sought to translate segrega-
tion data into supporting, moderate or strong PP1 rules
based on the number of meioses of the variant that are in-
formative for co-segregation [29, 30]. The rule adaptations
proposed here also address the discrepancy between the
rules for truncating and non-truncating variants in the
current guidelines. Truncating variants in genes where loss
of function is a known mechanism for the disease in ques-
tion will achieve a classification of at least likely patho-
genic, courtesy of the (very strong) PVS1 rule, assuming a
number of criteria are met [33]. While the weight of this
rule partly derives from the fact that a non-functional pro-
tein is likely to be produced by the truncating variant
(albeit with the caveats described by Richards et al. [1]), it
also reflects the rarity of such variants in the population
and consequently the high odds of a variant detected in a
patient being pathogenic (as seen withMYBPC3 truncating
variants in this study, with an EF > 0.99 and an OR of 115).
Non-truncating variant classes that are similarly highly
enriched in case cohorts should also have this evidence
more appropriately weighted when evaluating variants.
Although we have introduced a more quantitative
approach to variant classification in this study, we have
deliberately stayed within the framework of the ACMG/
AMP guidelines. These guidelines have been widely
adopted in clinical genetics laboratories, and therefore,
adaptations like those we have proposed here can be
easily and readily integrated into existing variant analysis
pipelines in these laboratories. In time, more compre-
hensive quantitative models assessing a wider range of
evidence classes, and likely incorporating machine learn-
ing algorithms, may be developed that could offer a fully
quantitative approach to variant interpretation. However,
there will likely be substantial technical and cultural ob-
stacles to be overcome before such novel methodologies
are routinely applied in clinical testing.
Our findings highlight the necessity of applying gene and
disease-specific expertise to both variant classification and
the customisation of ACMG/AMP guidelines [6]. As we
have shown, variant characteristics that are specific to the
genes and disease in question, such as clustering of case
variants in specific protein domains, are more powerful
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discriminators than generic techniques designed to be
applied genome wide, such as the widely used mis-
sense functional prediction algorithms. This has also
been recently demonstrated by an analysis of variation
in the RYR2 gene in catecholaminergic polymorphic
ventricular tachycardia [27]. Interestingly, the esti-
mated 14–20% increased yield of actionable variants
in sarcomeric genes described here is likely to have a
greater impact on HCM genetic testing yield than all
of the efforts over the last 10–20 years to identify
novel, non-sarcomeric genetic causes in this condition
[19] that have explained very few additional cases.
This highlights how efforts and resources to improve
variant interpretation and the yield of genetic testing
can be inefficiently allocated. While discovering valid
novel genes may advance our understanding of disease
and identify new therapeutic targets, an over-emphasis
on discovering “novel” causes of diseases may have
less translational impact than efforts to improve our
understanding of variation in known disease genes.
The publication and sharing of genetic data, as well
as evidence about variant consequences in resources
like ClinVar, is crucial for expanding our ability to
interpret the results of clinical genetic testing of
Mendelian disease [34]. This study also underscores
the importance of clinical laboratories and research
groups publishing and sharing genetic data with allele
frequencies across case cohorts as well as recording
observations in individual patients—a large proportion
of the HCM data in this study was published previ-
ously by the LMM [13] and OMGL [3] clinical labora-
tories. This will be even more critical for extending
this approach to rarer and less well-characterised
genetic diseases than cardiomyopathies. In addition,
further sequencing and publication of genetic data
from non-Caucasian populations is becoming a critical
issue across genetics [35], including Mendelian condi-
tions like cardiomyopathies. Large case cohorts, as
well as population data from resources like gnomAD,
from currently underrepresented population groups
will be needed to validate the methods described here
in non-Caucasians. However, the analysis of the pro-
spective HCM cohort in this study has also exposed
the limitations of relying on variant-specific evidence
such as segregation data for the interpretation of vari-
ants. Published segregation data was mostly restricted
to those variants that are already enriched in HCM
cases (and therefore can be used to increase confi-
dence in the variant classification by upgrading from
likely pathogenic to pathogenic) rather than enabling
rarer variants to be progressed from VUS to likely
pathogenic, highlighting the necessity of novel ap-
proaches to increase the sensitivity of genetic testing,
such as those described in this study.
Comparisons with other methods that assess region
pathogenicity
An alternative approach to identify functionally important
genic regions seeks those that are depleted in (missense)
variation in a reference population[36], in contrast to the
analysis presented here that seeks a regional enrichment
of variation in cases. Here depletion indicates negative
selection of variation, implying that variation is not toler-
ated. Sub-genic regions of constraint were identified in
only four of the HCM genes analysed in this study
(MYH7, FLNC, TNNC1, FHOD3). There is partial overlap
of the regions identified in this study (Fig. 2), e.g. a region
of high constraint in MYH7 from residues 1–916 broadly
corresponds to our HCM cluster (residues 167–931).
Whatever the method for identifying a region of interest,
empirical comparison of cases and controls provides a
direct assessment of the strength of association with a spe-
cific disease, enabling us to directly estimate the likelihood
of pathogenicity for variants in specific regions, as well as
detecting pathogenic clusters in other genes for which no
regional constraint data exists.
The EF (and OR) can of course be applied to calibrate
an appropriate PM1 rule strength irrespective of the
method by which the region is initially highlighted as
potentially important. For example, two recent studies
explored structure-function models in β-cardiac myosin
(MYH7) to identify residues that are key to protein func-
tion (and therefore intolerant of variation), with variants
affecting these residues enriched in case over population
reference cohorts. Homburger et al. modelled β-cardiac
myosin before and after the myosin power stroke and
identified the converter kinetic domain and myosin mesa
surface area as regions enriched in disease-associated
variants using a spatial scan statistic [37]. Alamo et al.
defined sites of inter- and intramolecular interaction be-
tween pairs of myosin heads (the interacting-heads
motif—IHM), noting that variants in HCM cases dispro-
portionately alter IHM residues [38]. The MYH7 resi-
dues identified by these studies largely overlap with the
HCM cluster we have identified by one-dimensional clus-
tering (Fig. 2). Particular groups of residues detected by
these analyses are highly enriched in disease-associated
variants (yielding higher EFs than our cluster), with 7
IHM groups yielding an EF > 0.99 and accounting for 44%
of variants found in HCM cases [38]. EF-based variant
analysis thus requires a balance between specificity and
sensitivity, or a tiered approach with different confidence
levels for pathogenicity.
Issues and limitations of this approach to variant
classification
The calculation of EFs for particular variant classes is
dependent on a number of factors. As we have previously
shown, it is critical to adopt stringent, disease-specific
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frequency thresholds when assessing putative pathogenic
variants [22]. Additionally, the choice of case and control/
population cohorts will influence how EFs are generated.
For cases, the use of clinical referral cohorts (the diagnos-
tic case series from different centres in Europe and North
America that we have employed in this study should be
reasonably representative of real-world referral patterns)
will produce more conservative EF values than highly
selected case series, but we believe these more cautious,
referral EFs are relevant to a clinical genetic setting. None-
theless, these may change as referral patterns change (e.g.
with increasing test availability). Although the use of
population reference data without well-defined pheno-
types has limitations, and is not optimally matched
technically (e.g. differences in sequencing coverage, as pre-
viously discussed [3]), we believe the advantages (popula-
tion size and ethnic diversity allowing more accurate
calculation of rare variant frequencies) outweigh the dis-
advantages. It is also crucially important to note that the
evidence described here should only be applied to asses-
sing variants from patients with the disease in question,
and not from incidental or secondary findings in healthy
individuals or those being sequenced in the context of
other conditions, as EFs correspond to the probability of
pathogenicity given that the variant is identified in an
individual with disease.
Although we have identified highly pathogenic variant
classes in a number of HCM genes, for others it is more
challenging to effectively differentiate between benign and
pathogenic variation. In particular, although we detected
some small case-enriched clusters of non-truncating vari-
ants in MYBPC3, these will correspond to only a small
proportion of such variants that are responsible for HCM
in up to 8% of cases. For such genes, further research and
larger datasets are needed to identify the protein regions
and specific residues at which variation is most likely to
cause disease. This could include analysis of protein struc-
ture, as demonstrated in the MYH7 studies described
above, or the development of computational prediction
techniques that are specific to (and validated in) key
disease genes, given the limitations of the generic and
consensus scores that we have observed in this study.
Genes like MYBPC3, i.e. those with a high diagnostic yield
but poor signal-noise ratio that impedes the statistical
prediction of pathogenicity, could also be prioritised for
high-throughput functional classification studies [39].
Conclusion
In conclusion, we have demonstrated that by combining
large case and control datasets, stringent population fre-
quency thresholds, and the detection of pathogenic clus-
ters in key disease genes, we can empirically estimate
the likelihood that rare variants in specific genes or
regions are pathogenic and can identify variant classes
with a high prior probability of pathogenicity. Using this
evidence to calibrate the appropriate weighting for rules
within the ACMG/AMP framework, we believe the yield
of genetic testing in diseases like HCM can be signifi-
cantly increased, with less dependence on the prior char-
acterisation of variants to define pathogenicity, while
retaining a robust statistical framework. This may help
to reduce the substantial false-negative rate associated
with the use of the current stringent variant interpret-
ation guidelines and increase the accuracy and sensitivity
of genetic testing. It may also help to address the ethni-
city bias associated with obtaining a positive result, en-
abling a more equitable application of genetic testing.
This study also reinforces the concept that disease and
gene-specific approaches are critical for accurate and
comprehensive variant analysis. Finally, this quantitative
approach moves us towards more transparent probabil-
istic variant classification for both Mendelian disease
genetics and precision medicine.
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